Cost-effectiveness study of antidiabetic drugs in type 2 diabetes mellitus patients from Mumbai, India

Dnyanesh Limaye; Krishna Todi; Jay Shroff; Ashutosh Ramaswamy; Priyanka Kulkarni; Vaidehi Limaye; Gerhard Fortwengel

doi:10.18203/2394-6040.ijcmph20173653

Authors

Dnyanesh Limaye UNRED research group. Hochschule Hannover, Faculty III, Expo Plaza 12, Hannover 30539, Germany.
Krishna Todi Institute of Chemical Technology, Mumbai, India
Jay Shroff Institute of Chemical Technology, Mumbai, India
Ashutosh Ramaswamy Institute of Chemical Technology, Mumbai, India
Priyanka Kulkarni Institute of Chemical Technology, Mumbai, India
Vaidehi Limaye UNRED research group. Hochschule Hannover, Faculty III, Expo Plaza 12, Hannover 30539, Germany.
Gerhard Fortwengel UNRED research group. Hochschule Hannover, Faculty III, Expo Plaza 12, Hannover 30539, Germany.

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20173653

Keywords:

Antidiabetic, Cost-effectiveness, Diabetes mellitus, India

Abstract

Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India.

Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability.

Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5).

Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness.

Metrics

Metrics Loading ...

Author Biography

Dnyanesh Limaye, UNRED research group. Hochschule Hannover, Faculty III, Expo Plaza 12, Hannover 30539, Germany.

Senior Scientist - Clinical research and Epidemiology

References

Kannan, Arshad, Senthil K. A study on drug utilization of oral hypoglycemic agents in Type-2 diabetic patients. Asian J Pharm Clin Res. 2011;5:60-4.

About Diabetes. Available at: http://www.who.int/

diabetes/publications/diabetes_booklet/en/ Accessed on 19 September 2016.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000and projections for 2030. Diabetes Care. 2004;27:1047-53.

Joshi SR, Parikh RM. India - diabetes capital of the world: now heading towards hypertension. J Assoc Physicians India. 2007;55:323–4.

Kumar A, Goel MK, Jain RB, Khanna P, Chaudhary V. India towards diabetes control: Key issues. Australas Med J. 2013;6(10):524-31.

Brunton L, Chabner B, Knollmann B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 12th Edition. 2010.

Whiting Dr, Guariguata L, Weil C, Shaw J. IDF Diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-21.

González-Villalpando C, López-Ridaura R, Campuzano JC. González-Villalpando ME. The status of diabetes care in Mexican population: Are we making a difference? Results of the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52(1):36–46.

Simpson SH, Corabian P, Jacobs P, Johnson JA. The cost of major comorbidity in people with diabetes mellitus. CMAJ. 2003;168(13):1661–7.

Yesudian C, Grepstad M, Visintin E, Ferrario A. The economic burden of diabetes in India: a review of the literature. Globalization Health. 2014;10:80.

Abdulganiyu G, Fola T. Cost-effectiveness analysis of anti-diabetic therapy in a university teaching hospital. Int J Pharm Sci Res. 2014;5(3):82-91.

Derosa G. Pioglitazone plus glimepiride: a promising alternative in metabolic control. Int J Clin Pract. 2007;61(153):28–36.

UKPDS Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care. 1998;21:87–92.

Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;28:2005–12.

Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Invest. 2014;5:701–8.

Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res. 1996;28:496–507.

Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas – a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract. 1995;28:115–37.

National Collaborating Centre for Chronic Conditions (UK). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). Royal College of Physicians (UK), London: 2008.

Kara H, David H, Jonathan JQ. Economics for Drug Management. In: Kara H, David H, Jonathan JQ, editors. Text Book of Managing Drug Supply. 2nd Edition. USA: Kumarian press inc; 1997: 401-430.